Literature DB >> 25734212

John Fitzpatrick: an appreciation.

William Watson, Mark Lawler.   

Abstract

Mesh：

Year:  2015        PMID： 25734212      PMCID： PMC4294620          DOI： 10.1634/theoncologist.2015-0005

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  3 in total

Review 1.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

2.  Prostate cancer risk assessment tools in an unscreened population.

Authors:  D J Lundon; B D Kelly; R Foley; S Loeb; J M Fitzpatrick; R W G Watson; E Rogers; G C Durkan; K Walsh
Journal:  World J Urol       Date:  2014-08-05       Impact factor: 4.226

3.  Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Authors:  John M Fitzpatrick; Joaquim Bellmunt; Karim Fizazi; Axel Heidenreich; Cora N Sternberg; Bertrand Tombal; Antonio Alcaraz; Amit Bahl; Sergio Bracarda; Giuseppe Di Lorenzo; Eleni Efstathiou; Stephen P Finn; Sophie Fosså; Silke Gillessen; Pirkko-Liisa Kellokumpu-Lehtinen; Frédéric E Lecouvet; Stephane Oudard; Theo M de Reijke; Craig N Robson; Maria De Santis; Bostjan Seruga; Ronald de Wit
Journal:  Eur J Cancer       Date:  2014-04-03       Impact factor: 9.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.